Enterprise Value to EBITDA Multiple ratio Analysis of Immuneering Corp - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointLatest FY EV to EBITDA
Period Ending - Dec-23
Very Poor EV to EBITDA
341.38
Period Ending - Dec-22
Excellent EV to EBITDA
0.663
Growth
51421.20 %
Trailing Twelve Months EV to EBITDA
Period Ending - Dec-23
Excellent EV to EBITDA
1.38
EV to EBITDA Analysis of Immuneering Corp
| Enterprise Value to EBITDA of Immuneering Corp with value of 341.38 implies that the company is overvalued. |
| EV to EBITDA Ratio of IMRX rose handsomely by 51421.20 % this year. |
| EV to EBITDA Ratio with value of 341.38 was highest in Year Dec-23 in last Five Years. |
| EV to EBITDA Ratio with value of 0.160 was lowest in Year Dec-19 in last Five Years. |
| Latest EV to EBITDA Ratio with value of 341.38 is Greater than Average EV to EBITDA of 69.05 in last five years. |
Other EV to EBITDA Related Info of IMRX that may interest you.
Immuneering Corp Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| IMRX | 1.47 | 1.54 | 4.55 % | Biotechnology |
Defination of Enterprise Value to EBITDA Multiple
Enterprise Value-to-EBITDA Ratio is used to compare a company's Enterprise Value to its EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization). It is useful to determine the value of a company, whether it is undervalued or overvalued. more ..
EV to EBITDA Related Ratios
| EBITDAMargin | EVToRevenue | PriceToEarningRatio |
Tsr Value Index
| No Significant Value | |
FY - Historical Enterprise Value to EBITDA Multiple of Immuneering Corp
| Period | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 |
|---|---|---|---|---|---|
| EV to EBITDA | 341.38 | 0.663 | 1.61 | 1.44 | 0.160 |
| Change | 51421.20 % | -58.93 % | 12.14 % | 801.82 % |
FY Chart of Enterprise Value to EBITDA Multiple of Immuneering Corp
Note : All Data Generated at the End of Trading Hours (EOD Data)